<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576431</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-TRK-15002</org_study_id>
    <nct_id>NCT02576431</nct_id>
  </id_info>
  <brief_title>Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)</brief_title>
  <official_title>A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a
      fusion of NTRK1, NTRK2 or NTRK3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, multi-center, open-label study of patients with advanced solid tumors
      harboring a fusion of NTRK1, NTRK2 or NTRK3. Patients with NTRK1, NTRK2 or NTRK3
      fusion-positive cancers will be identified through molecular assay.

      LOXO-101 will be administered at 100mg twice daily (BID), with each cycle consisting of 28
      days of dosing administered on a continuous basis.

      The study will include 8 cohorts of patients with tumors bearing NTRK fusions, including non
      small cell lung cancer, thyroid cancer, sarcoma, colorectal cancer, salivary gland cancer,
      biliary cancer and primary CNS tumor, as well as a cohort that will enroll patients not
      included in the histologies listed above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Best Overall Response of confirmed CR or PR as measured by RECIST 1.1 or RANO criteria as appropriate to tumor type</measure>
    <time_frame>Up to 30 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion up to 42 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of months from the initiation of LOXO-101 to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the safety profile and tolerability of LOXO-101</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Thyroid Neoplasms</condition>
  <condition>Sarcoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Salivary Gland Neoplasms</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <condition>Brain Neoplasm, Primary</condition>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Melanoma</condition>
  <condition>Solid Tumors</condition>
  <condition>Glioblastoma</condition>
  <condition>Bile Duct Neoplasms</condition>
  <condition>Astrocytoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Pontine Glioma</condition>
  <arm_group>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salivary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult Solid Tumors Measurable Disease by RECIST 1.1 Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary CNS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Brain Tumor Measurable by RANO Oral LOXO-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All Other Solid Tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumor Histology not in Cohorts 1-7 Evaluable but not Measurable Disease Oral LOXO-101</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-101</intervention_name>
    <description>Oral capsule of LOXO-101 - 100mg BID</description>
    <arm_group_label>Non Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>Thyroid</arm_group_label>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_label>Salivary</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Primary CNS</arm_group_label>
    <arm_group_label>All Other Solid Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Locally-advanced or metastatic malignancy with an NTRK1, NTRK2 or NTRK3 gene fusion,
             identified through molecular assays as routinely performed at CLIA or other
             similarly-certified laboratories.

          2. Subjects must have received prior standard therapy appropriate for their tumor type
             and stage of disease, or in the opinion of the Investigator, would be unlikely to
             tolerate or derive clinical benefit from appropriate standard of care therapy.

          3. Subjects must have at least one measurable lesion as defined by RECIST 1.1
             (Eisenhauer 2009). Subjects without RECIST measurable disease (e.g., evaluable
             disease only) will be eligible for enrollment to Cohort 8, regardless of tumor type.
             Subjects in Cohort 7 (primary CNS tumors) should meet the following criteria:

               -  Have received prior treatment including radiation and/or chemotherapy, with
                  radiation completed &gt; 12 weeks prior to C1D1 of therapy.

               -  Have ≥ 1 site of bi-dimensionally measurable disease (confirmed by magnetic
                  resonance imaging [MRI] and evaluable by RANO criteria), with the size of at
                  least one of the measurable lesions ≥ 1 cm in each dimension and noted on more
                  than one imaging slice.

               -  Imaging study performed within 28 days before enrollment while on stable dose
                  steroid medication for at least 5 days immediately before and during the imaging
                  study.

          4. Adequate organ function as defined by the following criteria:

               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) &lt; 2.5
                  upper limit of normal (ULN), or AST and ALT &lt; 5 ULN if liver function
                  abnormalities are due to underlying malignancy.

               -  Total bilirubin &lt; 2.0 ULN. Subjects with a known history of Gilberts Disease and
                  an isolated elevation of indirect bilirubin are eligible.

               -  Serum creatinine &lt; 2.0 ULN OR an estimated glomerular filtration rate ≥ 30
                  mL/minute using the Cockroft-Gault formula.

          5. Ability to swallow capsules,

        Key Exclusion Criteria:

          1. Symptomatic or unstable brain metastases. (Note: Subjects with asymptomatic brain
             metastases are eligible to participate in the study). Subjects with primary CNS
             tumors are eligible.

          2. Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Ku, MD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maegan Deegan</last_name>
    <phone>1-855-NTRK-123</phone>
    <email>maegan@loxooncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lia Donahue</last_name>
    <phone>1-855-NTRK-123</phone>
    <email>lia@loxooncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Rosen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Standford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Drilon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wafik El-Deiry, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Berlin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Deeken, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Ma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Lassen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray McDermott, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keunchil Park, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 15, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NTRK Fusion Positive</keyword>
  <keyword>LOXO-101</keyword>
  <keyword>Loxo</keyword>
  <keyword>TRK</keyword>
  <keyword>TRK Fusion</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>ETV6</keyword>
  <keyword>NTRK</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
